New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Check out this training for the full story!
Johannes Jacobus  Oosthuizen net worth and biography

Johannes Oosthuizen Biography and Net Worth

Insider of Merck & Co., Inc.
Jannie Oosthuizen leads Merck Human Health U.S., which is Merck’s largest business globally. He is responsible for P&L, strategy, customer engagement and commercialization in the U.S. for Merck’s broad portfolio of human health medicines and vaccines.

Jannie joined the company in 2014 to lead the Human Health oncology business in Asia Pacific and Latin America, then led Merck’s business in Japan from 2016 to 2020, and then led Global Marketing for Oncology. In each of these roles, Jannie successfully created and implemented new strategies and innovative commercial models that delivered strong, leveraged growth and established Merck as a leading business in those markets and therapeutic areas.

Jannie has deep experience in a broad range of global markets and therapeutic areas, and in building and leading high-performing teams. Prior to Merck, Jannie spent 20 years at Eli Lilly in a wide range of commercial and marketing roles with increasing responsibility. He began his career with Eli Lilly in 1993 in his home country of South Africa. Jannie is a pharmacist by training and graduated from North-West University in South Africa. He has lived and worked in six countries spanning five continents with his wife and three children.

What is Johannes Jacobus Oosthuizen's net worth?

The estimated net worth of Johannes Jacobus Oosthuizen is at least $1.92 million as of November 9th, 2023. Mr. Oosthuizen owns 18,191 shares of Merck & Co., Inc. stock worth more than $1,922,971 as of December 6th. This net worth approximation does not reflect any other assets that Mr. Oosthuizen may own. Learn More about Johannes Jacobus Oosthuizen's net worth.

How do I contact Johannes Jacobus Oosthuizen?

The corporate mailing address for Mr. Oosthuizen and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Johannes Jacobus Oosthuizen's contact information.

Has Johannes Jacobus Oosthuizen been buying or selling shares of Merck & Co., Inc.?

Over the course of the past ninety days, Johannes Jacobus Oosthuizen has sold $213,052.78 in shares of Merck & Co., Inc. stock. Most recently, Johannes Jacobus Oosthuizen sold 2,081 shares of the business's stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $102.38, for a transaction totalling $213,052.78. Following the completion of the sale, the insider now directly owns 18,191 shares of the company's stock, valued at $1,862,394.58. Learn More on Johannes Jacobus Oosthuizen's trading history.

Who are Merck & Co., Inc.'s active insiders?

Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.

Are insiders buying or selling shares of Merck & Co., Inc.?

During the last year, Merck & Co., Inc. insiders bought shares 3 times. They purchased a total of 150 shares worth more than $15,886.16. During the last year, insiders at the sold shares 16 times. They sold a total of 643,192 shares worth more than $73,406,716.13. The most recent insider tranaction occured on November, 9th when insider Johannes Jacobus Oosthuizen sold 2,081 shares worth more than $213,052.78. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..

Information on this page was last updated on 11/9/2023.

Johannes Jacobus Oosthuizen Insider Trading History at Merck & Co., Inc.

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2023Sell2,081$102.38$213,052.7818,191View SEC Filing Icon  
11/9/2022Sell1,795$103.21$185,261.9516,731View SEC Filing Icon  
11/7/2022Sell45,561$99.47$4,531,952.6718,526View SEC Filing Icon  
See Full Table

Johannes Jacobus Oosthuizen Buying and Selling Activity at Merck & Co., Inc.

This chart shows Johannes Jacobus Oosthuizen's buying and selling at Merck & Co., Inc. by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Merck & Co., Inc. Company Overview

Merck & Co., Inc. logo
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Read More

Today's Range

Now: $105.71
Low: $105.43
High: $106.57

50 Day Range

MA: $102.94
Low: $100.17
High: $106.23

2 Week Range

Now: $105.71
Low: $96.36
High: $119.65


1,941,041 shs

Average Volume

7,551,212 shs

Market Capitalization

$267.87 billion

P/E Ratio


Dividend Yield